Yan Xu (Xu Yan)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 44

Top Topics

Magnetic Resonance Imaging

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Thoracic cancer

Cancer medicine

Cancer management and research

This page only lists publications with an associated author ORCID identifier.

Publications

Zhaojue Wang, Yang Wu, Tao Lu, Yan Xu, Minjiang Chen, Wei Zhong, Jing Zhao, Mengzhao Wang
The outcomes of different regimens depend on the molecular subtypes of pulmonary large-cell neuroendocrine carcinoma: A retrospective study in China. Cancer medicine (2024)
Yuequan Shi, Yan Xu, Mengzhao Wang
Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation. BMC cancer 24 (1) (2024)
Yuequan Shi, Yan Xu, Mengzhao Wang
Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation. BMC cancer 24 (1) (2024)
Zhaojue Wang, Yang Wu, Tao Lu, Yan Xu, Minjiang Chen, Wei Zhong, Jing Zhao, Mengzhao Wang
The outcomes of different regimens depend on the molecular subtypes of pulmonary large-cell neuroendocrine carcinoma: A retrospective study in China. Cancer medicine (2024)
Zhaojue Wang, Yang Wu, Tao Lu, Yan Xu, Minjiang Chen, Wei Zhong, Jing Zhao, Mengzhao Wang
The outcomes of different regimens depend on the molecular subtypes of pulmonary large-cell neuroendocrine carcinoma: A retrospective study in China. Cancer medicine (2024)
Yunxin Liu, Xiaoyi Feng, Yan Xu, Siyuan Yu, Mengzhao Wang
Clinical manifestation and outcome of lung cancer patients with ocular metastasis: 16 case reports and systematic review. Thoracic cancer (2024)
Yuequan Shi, Yan Xu, Mengzhao Wang
Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation. BMC cancer 24 (1) (2024)
Zhaojue Wang, Yang Wu, Tao Lu, Yan Xu, Minjiang Chen, Wei Zhong, Jing Zhao, Mengzhao Wang
The outcomes of different regimens depend on the molecular subtypes of pulmonary large-cell neuroendocrine carcinoma: A retrospective study in China. Cancer medicine 13 (1) (2024)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer 14 (8) (2023)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Qing Zhou, Xiangning Liu, Ji Li, Bing Tong, Yan Xu, Min-Jiang Chen, Xiaoyan Liu, Xiaoxing Gao, Yuequan Shi, Jing Zhao, Wei Zhong, Mengzhao Wang
Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Qing Zhou, Xiangning Liu, Ji Li, Bing Tong, Yan Xu, Min-Jiang Chen, Xiaoyan Liu, Xiaoxing Gao, Yuequan Shi, Jing Zhao, Wei Zhong, Mengzhao Wang
Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Thoracic cancer (2023)
Haoran Zhang, Dongming Zhang, Jia Liu, Yuequan Shi, Xiaoyan Liu, Min-Jiang Chen, Wei Zhong, Jing Zhao, Yan Xu, Mengzhao Wang
Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC. Thoracic cancer (2023)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer 14 (8) (2023)
Qing Zhou, Xiangning Liu, Ji Li, Bing Tong, Yan Xu, Min-Jiang Chen, Xiaoyan Liu, Xiaoxing Gao, Yuequan Shi, Jing Zhao, Wei Zhong, Mengzhao Wang
Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer (2023)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer 14 (8) (2023)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer (2023)
Xiao-Yan Si, Xueqing Zheng, Xinlun Tian, Hanping Wang, Yan Xu, Jing Zhao, Min-Jiang Chen, Wei Zhong, Mengzhao Wang, Li Zhang, Xiao-Tong Zhang
Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case-control study. Thoracic cancer (2023)
Xiaoxing Gao, Ruili Pan, Min-Jiang Chen, Jing Zhao, Wei Zhong, Hanping Wang, Xiao-Yan Si, Xiao-Tong Zhang, Li Zhang, Yan Xu, Mengzhao Wang
Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. Thoracic cancer 13 (7) (2022)
Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, Jian Fang, D Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola W Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Lyudmila Bazhenova, Chee Khoon Lee, Bo Gao, Yan Xu, Wei-Hsun Hsu, Li Zheng, Pasi A Janne
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Cancer discovery 12 (7) (2022)
Bei Tan, Yun-Xin Liu, Hao Tang, Dan Chen, Yan Xu, Min-Jiang Chen, Yue Li, Meng-Zhao Wang, Jia-Ming Qian
Gut microbiota shed new light on the management of immune-related adverse events. Thoracic cancer 13 (19) (2022)
Bei Tan, Min-Jiang Chen, Qi Guo, Hao Tang, Yue Li, Xin-Miao Jia, Yan Xu, Liang Zhu, Meng-Zhao Wang, Jia-Ming Qian
Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events. Thoracic cancer 12 (12) (2021)
Yangchun Gu, Yan Xu, Hongqing Zhuang, Weijuan Jiang, Hua Zhang, Xiaofeng Li, Yonggang Liu, Li Ma, Dahai Zhao, Yuan Cheng, Yan Yu, Ping Liu, Jianwen Qin, Xueqin Chen, Junzhen Gao, Mengzhao Wang, Li Liang, Baoshan Cao
Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique. Thoracic cancer 12 (23) (2021)
Jun Ni, Xiao-Tong Zhang, Hanping Wang, Xiao-Yan Si, Yan Xu, Jing Zhao, Min-Jiang Chen, Li Zhang, Mengzhao Wang
Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period. Thoracic cancer 13 (4) (2021)
Yuequan Shi, Xiaoyan Liu, Juan Du, Dongming Zhang, Jia Liu, Min-Jiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang
Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. Thoracic cancer (2021)
Yan Xu, Ji Li, Bing Tong, Minjiang Chen, Xiaoyan Liu, Wei Zhong, Jing Zhao, Mengzhao Wang
Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer. ESMO open 5 (4) (2021)
Min-Jiang Chen, Yan Xu, Jing Zhao, Ji Li, Xiangning Liu, Wei Zhong, Mengzhao Wang
Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer. Thoracic cancer 12 (17) (2021)
Yuequan Shi, Ji Li, Min-Jiang Chen, Hongsheng Liu, Dongjie Ma, Yuxiao Lin, Mengzhao Wang, Yan Xu
Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response. Thoracic cancer (2021)
Xiaoling Qiu, Hongge Liang, Wei Zhong, Jing Zhao, Min-Jiang Chen, Zhaohui Zhu, Yan Xu, Mengzhao Wang
Prognostic impact of maximum standardized uptake value on 18 F-FDG PET/CT imaging of the primary lung lesion on survival in advanced non-small cell lung cancer: A retrospective study. Thoracic cancer 12 (6) (2021)
Yuequan Shi, Jian Fang, Cheng-Zhi Zhou, Anwen Liu, Yan Wang, Qingwei Meng, Cuimin Ding, Bin Ai, Yangchun Gu, Yu Yao, Hong Sun, Hui Guo, Cuiying Zhang, Xia Song, Junling Li, Bei Xu, Zhiqiang Han, Meijun Song, Tingyu Tang, Peifeng Chen, Hongmin Lu, Yongjie Shui, Guangyuan Lou, Dongming Zhang, Jia Liu, Xiaoyan Liu, Xiangning Liu, Xiaoxing Gao, Qing Zhou, Min-Jiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. Thoracic cancer 13 (3) (2021)
Jun Ni, Wang Hanping, Xiao-Yan Si, Yan Xu, Wang Mengzhao, Xiao-Tong Zhang, Zhang Li
Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. Thoracic cancer 11 (7) (2020)
Yan Xu, Hongsheng Liu, Ke Hu, Mengzhao Wang
Clinical recommendations on lung cancer management during the COVID-19 pandemic. Thoracic cancer 11 (7) (2020)
Min-Jiang Chen, Qiang Li, Yan Xu, Jing Zhao, Li Zhang, Lijuan Wei, Wei Zhong, Mengzhao Wang
Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. Thoracic cancer 11 (7) (2020)
Hongge Liang, Yan Xu, Minjiang Chen, Wei Zhong, Mengzhao Wang, Jing Zhao
Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Thoracic cancer 11 (4) (2020)
Yongjian Liu, Yan Xu, Xinlun Tian, Hui Huang, Xiaomeng Hou, Minjiang Chen, Wei Zhong, Jing Zhao, Jinming Gao, Jinglan Wang, Juhong Shi, Mengzhao Wang
Thymic neoplasms patients complicated with bronchiectasis: Case series in a Chinese hospital and literature review. Thoracic cancer 10 (4) (2019)
Hongge Liang, Di Ma, Yan Xu, Jing Zhao, Min-Jiang Chen, Xiaoyan Liu, Wei Zhong, Junling Li, Mengzhao Wang
Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib. Cancer management and research 11 (2019)
Hongge Liang, Xia Song, Yuhui Zhang, Shucai Zhang, Fang Li, Jian Fang, Junling Li, Li Liang, Ligong Nie, Kewei Ma, Liangming Zhang, Xiaohong Wang, Junjun Xu, Yanxia Wei, Jinghui Wang, Qi Song, Guangming Tian, Yuxin Mu, Yangchun Gu, Lei Yang, Ping Sun, Wei Zhong, Jing Zhao, Yan Xu, Minjiang Chen, Mengzhao Wang
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study. Thoracic cancer 10 (7) (2019)
Shixuan Liu, Yan Xu, Nai Shi Li, Shi Chen, Shangzhu Zhang, Linyi Peng, Wei Bai, Jinglan Wang, Jinming Gao, Xiaofeng Zeng, Juhong Shi, Mengzhao Wang
Pituitary Involvement in Granulomatosis with Polyangiitis: A Retrospective Analysis in a Single Chinese Hospital and a Literature Review. International journal of endocrinology 2019 (2019)
Yan Xu, Wei Zhong, Minjiang Chen, Jing Zhao, Mengzhao Wang
ALK-rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report. Thoracic cancer 9 (8) (2018)
Yan Xu, Juhong Shi
Disseminated Actinomycosis. The New England journal of medicine 379 (11) (2018)
Yan Xu, Li Zhang, Jian Fang, Ziping Wang, Junling Li, Lin Li, Bin Ai, Ligong Nie, Xinlin Mu, Li Liang, Shucai Zhang, Yuhui Zhang, Yuguang Song, Xia Song, Ye Wang, Tao Xin, Bo Jin, Xiaohong Wang, Cuimin Ding, Mengzhao Wang
Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). Thoracic cancer 9 (12) (2018)
Yan Xu, Wenbing Xu, Yongjian Liu, Xinlun Tian, Kaifeng Xu, Juhong Shi, Mengzhao Wang, Baiqiang Cai, Min Peng
Pulmonary hypertension associated with combined fibrosing mediastinitis and bronchial anthracofibrosis: A retrospective analysis in a single Chinese hospital. The clinical respiratory journal 12 (3) (2017)